The U.S. Food and Drug Administration (FDA) has issued a cautionary notice regarding the increased risks associated with compounded versions of Novo Nordisk’s weight-loss and diabetes medications. The alert follows reports of serious adverse events, including cases necessitating hospitalization, potentially linked to dosing errors with these compounded drugs.
The FDA’s warning underscores the dangers of compounded medications, which may contain additional ingredients not present in the original formulations. These discrepancies, combined with the potential for patient miscalculation and provider error, elevate the risk of overdose. The agency has advised healthcare providers and compounding pharmacies to ensure accurate dosage instructions and appropriate syringe sizes to mitigate these risks.
Compounded drug overdoses can lead to severe health issues such as intense nausea, vomiting, and hypoglycemia. The surge in demand for these medications has resulted in significant shortages and a burgeoning market for less regulated, and sometimes counterfeit, alternatives.
The FDA has also raised alarms about the prevalence of counterfeit versions of Novo Nordisk’s diabetes medication Ozempic, along with other weight-loss drugs such as Novo’s Wegovy and Eli Lilly’s Zepbound. These concerns reflect the broader issue of authenticity in the rapidly expanding market for such drugs.
Semaglutide, the active ingredient in both Wegovy and Ozempic, is part of the GLP-1 class of medications, designed to manage blood sugar levels and in
Related topics:
Irregular Sleep Patterns Increase Risk of Type 2 Diabetes
Consistent Sleep May Help Prevent Diabetes, Study Suggests
Massachusetts Lawmakers Propose Free Medications for Asthma, Diabetes, and Heart Conditions
